Although we have a general idea of the significant role of chemerin/chemR23 axis in obesity-related vascular dysfunction, it remains a pity that there is almost no drug circulating in the market targeting chemerin/chemR23 axis. The gene discussed is RARRES2; the disease is Obesity.